...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Expectations for the AGM?
4
Dec 06, 2020 12:17PM
4
Dec 06, 2020 03:13PM
6
Dec 08, 2020 05:51PM
1
Dec 10, 2020 01:00PM

"The Royalty shares in my opinion would have to be excluded to make RVX saleable."

They can't just exclude them without compensation to Zenith. Perhaps a negotiated cash payment to remove them.  RVX just sells for less than it would if there were no royalty shares.

 

2
Dec 10, 2020 01:51PM
3
Dec 10, 2020 02:35PM
3
Dec 10, 2020 02:55PM
Share
New Message
Please login to post a reply